382 related articles for article (PubMed ID: 16952014)
1. Transgenic mice expressing PAX3-FKHR have multiple defects in muscle development, including ectopic skeletal myogenesis in the developing neural tube.
Finckenstein FG; Davicioni E; Osborn KG; Cavenee WK; Arden KC; Anderson MJ
Transgenic Res; 2006 Oct; 15(5):595-614. PubMed ID: 16952014
[TBL] [Abstract][Full Text] [Related]
2. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3.
Anderson MJ; Shelton GD; Cavenee WK; Arden KC
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1589-94. PubMed ID: 11171995
[TBL] [Abstract][Full Text] [Related]
3. Mouse mesenchymal stem cells expressing PAX-FKHR form alveolar rhabdomyosarcomas by cooperating with secondary mutations.
Ren YX; Finckenstein FG; Abdueva DA; Shahbazian V; Chung B; Weinberg KI; Triche TJ; Shimada H; Anderson MJ
Cancer Res; 2008 Aug; 68(16):6587-97. PubMed ID: 18701482
[TBL] [Abstract][Full Text] [Related]
4. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function.
Keller C; Arenkiel BR; Coffin CM; El-Bardeesy N; DePinho RA; Capecchi MR
Genes Dev; 2004 Nov; 18(21):2614-26. PubMed ID: 15489287
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome analyses based on genetic screens for Pax3 myogenic targets in the mouse embryo.
Lagha M; Sato T; Regnault B; Cumano A; Zuniga A; Licht J; Relaix F; Buckingham M
BMC Genomics; 2010 Dec; 11():696. PubMed ID: 21143873
[TBL] [Abstract][Full Text] [Related]
6. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
Sublett JE; Jeon IS; Shapiro DN
Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
[TBL] [Abstract][Full Text] [Related]
7. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence.
Linardic CM; Naini S; Herndon JE; Kesserwan C; Qualman SJ; Counter CM
Cancer Res; 2007 Jul; 67(14):6691-9. PubMed ID: 17638879
[TBL] [Abstract][Full Text] [Related]
8. Normal and rearranged PAX3 expression in human rhabdomyosarcoma.
Frascella E; Toffolatti L; Rosolen A
Cancer Genet Cytogenet; 1998 Apr; 102(2):104-9. PubMed ID: 9546061
[TBL] [Abstract][Full Text] [Related]
9. Structural and functional studies of FKHR-PAX3, a reciprocal fusion gene of the t(2;13) chromosomal translocation in alveolar rhabdomyosarcoma.
Hu Q; Yuan Y; Wang C
PLoS One; 2013; 8(6):e68065. PubMed ID: 23799156
[TBL] [Abstract][Full Text] [Related]
10. Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.
Lagutina I; Conway SJ; Sublett J; Grosveld GC
Mol Cell Biol; 2002 Oct; 22(20):7204-16. PubMed ID: 12242297
[TBL] [Abstract][Full Text] [Related]
11. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
12. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
13. Validation of met as a therapeutic target in alveolar and embryonal rhabdomyosarcoma.
Taulli R; Scuoppo C; Bersani F; Accornero P; Forni PE; Miretti S; Grinza A; Allegra P; Schmitt-Ney M; Crepaldi T; Ponzetto C
Cancer Res; 2006 May; 66(9):4742-9. PubMed ID: 16651427
[TBL] [Abstract][Full Text] [Related]
14. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
15. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
16. The cooperative transforming effects of PAX3-FKHR and IGF-II on mouse myoblasts.
Wang W; Slevin M; Kumar S; Kumar P
Int J Oncol; 2005 Oct; 27(4):1087-96. PubMed ID: 16142327
[TBL] [Abstract][Full Text] [Related]
17. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: implications for alveolar rhabdomyosarcoma cell of origin.
Keller C; Hansen MS; Coffin CM; Capecchi MR
Genes Dev; 2004 Nov; 18(21):2608-13. PubMed ID: 15520281
[TBL] [Abstract][Full Text] [Related]
18. Analysis of genetic events that modulate the oncogenic and growth suppressive activities of the PAX3-FKHR fusion oncoprotein.
Xia SJ; Rajput P; Strzelecki DM; Barr FG
Lab Invest; 2007 Apr; 87(4):318-25. PubMed ID: 17297479
[TBL] [Abstract][Full Text] [Related]
19. An engineered PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene.
Fredericks WJ; Ayyanathan K; Herlyn M; Friedman JR; Rauscher FJ
Mol Cell Biol; 2000 Jul; 20(14):5019-31. PubMed ID: 10866659
[TBL] [Abstract][Full Text] [Related]
20. Transgenic rescue of congenital heart disease and spina bifida in Splotch mice.
Li J; Liu KC; Jin F; Lu MM; Epstein JA
Development; 1999 Jun; 126(11):2495-503. PubMed ID: 10226008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
